243 related articles for article (PubMed ID: 32552451)
1. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
2. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
3. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
Dong G; Huang B; Verbeeck J; Cui Y; Song J; Gamalo-Siebers M; Wang D; Hoaglin DC; Seifu Y; Mütze T; Kolassa J
Pharm Stat; 2023 Jan; 22(1):20-33. PubMed ID: 35757986
[TBL] [Abstract][Full Text] [Related]
4. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
Kawahara T; Shinozaki T; Matsuyama Y
BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
[TBL] [Abstract][Full Text] [Related]
5. Win-loss parameters for right-censored event data, with application to recurrent events.
Parner ET; Overgaard M
Stat Med; 2023 Dec; 42(30):5723-5735. PubMed ID: 37897052
[TBL] [Abstract][Full Text] [Related]
6. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
7. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
8. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study).
Yoshida M; Matsuyama Y; Ohashi Y;
Clin Trials; 2007; 4(4):318-28. PubMed ID: 17848493
[TBL] [Abstract][Full Text] [Related]
9. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
10. Calibration plots for multistate risk predictions models.
Pate A; Sperrin M; Riley RD; Peek N; Van Staa T; Sergeant JC; Mamas MA; Lip GYH; O'Flaherty M; Barrowman M; Buchan I; Martin GP
Stat Med; 2024 May; ():. PubMed ID: 38720592
[TBL] [Abstract][Full Text] [Related]
11. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
12. On logistic regression with right censored data, with or without competing risks, and its use for estimating treatment effects.
Blanche PF; Holt A; Scheike T
Lifetime Data Anal; 2023 Apr; 29(2):441-482. PubMed ID: 35799026
[TBL] [Abstract][Full Text] [Related]
13. Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring.
Schaubel DE; Wei G
Biometrics; 2011 Mar; 67(1):29-38. PubMed ID: 20560935
[TBL] [Abstract][Full Text] [Related]
14. Model selection for survival individualized treatment rules using the jackknife estimator.
Honvoh GD; Cho H; Kosorok MR
BMC Med Res Methodol; 2022 Dec; 22(1):328. PubMed ID: 36550398
[TBL] [Abstract][Full Text] [Related]
15. Generalized pairwise comparisons for censored data: An overview.
Deltuvaite-Thomas V; Verbeeck J; Burzykowski T; Buyse M; Tournigand C; Molenberghs G; Thas O
Biom J; 2023 Feb; 65(2):e2100354. PubMed ID: 36127290
[TBL] [Abstract][Full Text] [Related]
16. Addressing issues associated with evaluating prediction models for survival endpoints based on the concordance statistic.
Wang M; Long Q
Biometrics; 2016 Sep; 72(3):897-906. PubMed ID: 26756274
[TBL] [Abstract][Full Text] [Related]
17. The asymptotic distribution of the Net Benefit estimator in presence of right-censoring.
Ozenne B; Budtz-Jørgensen E; Péron J
Stat Methods Med Res; 2021 Nov; 30(11):2399-2412. PubMed ID: 34633267
[TBL] [Abstract][Full Text] [Related]
18. Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring.
Chakladar S; Rosin S; Hudgens MG; Halloran ME; Clemens JD; Ali M; Emch ME
Biometrics; 2022 Jun; 78(2):777-788. PubMed ID: 33768557
[TBL] [Abstract][Full Text] [Related]
19. Augmented and doubly robust G-estimation of causal effects under a Structural nested failure time model.
Mertens K; Vansteelandt S
Biometrics; 2018 Jun; 74(2):472-480. PubMed ID: 28742252
[TBL] [Abstract][Full Text] [Related]
20. Estimating lifetime or episode-of-illness costs under censoring.
Basu A; Manning WG
Health Econ; 2010 Sep; 19(9):1010-28. PubMed ID: 20665908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
